U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Drugs
  3. News & Events for Human Drugs
  4. An In-Depth Look at the Final FDA Guidance: Bioavailability Studies Submitted in NDAs or INDs – General Considerations - 10/26/2022
  1. News & Events for Human Drugs

Webcast | Virtual

Event Title
An In-Depth Look at the Final FDA Guidance: Bioavailability Studies Submitted in NDAs or INDs – General Considerations
October 26, 2022

Date:
October 26, 2022
Time:
1:00 p.m. - 4:00 p.m. ET

 

Topics & Presentations

Speakers

An in-depth look at the final FDA Guidance: Bioavailability Studies Submitted in NDAs or INDs – General Considerations

 

Opening Comments

Ethan Stier, PhD.
Associate Director, Lifecycle Management
Immediate Office (IO) | Office of Clinical Pharmacology (OCP)
Office of Translational Sciences (OTS) | CDER

Bioavailability Studies Submitted in NDAs and INDs – General Considerations

Dakshina Chilukuri, PhD.
Team Leader
Division of Infectious Disease Pharmacology (DIDP) | OCP | CDER

Bioavailability Determination: Special Topics

Jayabharathi Vaidyanathan, PhD.
Associate Director for Therapeutic Review
Division of Cardiometabolic and Endocrine Pharmacology (DCEP) | OCP CDER

Relative Bioavailability Evaluation: Potential for Using Pharmacodynamic and Non-Traditional Pharmacokinetic Endpoints

Kofi A. Kumi, Ph.D., R. Ph.
Senior Reviewer, Clinical Pharmacology
Division of Neuropsychiatric Pharmacology (DNP) | OCP | OTS | CDER

Recommended In Vitro Studies

Okponanabofa Eradiri, PhD
Branch Chief
Division of Biopharmaceutics (DP) | Office of New Drug Products (ONDP)Office of Pharmaceutical Quality (OPQ) | CDER | FDA 

Q&A Discussion with All Presenters

Ethan Stier, Dakshina Chilukuri, Jayabharathi Vaidyanathan, Kofi A. Kumi, and Okponanabofa Eradiri

 

Visit CDER Small Business and Industry Assistance Page

ABOUT THIS WEBINAR

FDA will provide additional clarity to the final guidance with respect to Agency expectations for submissions containing BA information for drug products, and will:

  • Discuss select case studies on various bioavailability (BA) related subtopics (e.g. pharmacodynamic (PD) endpoints, endogenous compound Narrow Therapeutic Index (NTI), biowaivers).
  • Conduct a QnA panel to make available an opportunity for attendees to interact with subject matter experts

INTENDED AUDIENCE

  • Regulatory Scientists assessing bioavailability studies as part of IND/NDA/BLA submissions
  • Research Coordinators overseeing in vivo studies in the context of IND/NDA/BLA submissions
  • Drug Development/New Drug industry scientists involved with bioavailability studies for support of a new/existing IND/NDA/BLA dossier.
  • Foreign regulators

TOPICS COVERED

  • General BA considerations
  • Pre/post approval changes
  • In-vitro/in silico approaches to BA
  • Alcohol considerations in relative BA

FDA SPEAKERS

1:00 - 1:10: SBIA Welcome and Overview

1:10 - 1:20: Opening Comments
Ethan Stier, PhD.
Associate Director, Lifecycle Management
Immediate Office (IO) | Office of Clinical Pharmacology (OCP)
Office of Translational Sciences (OTS) | CDER

1:20 - 1:50: Bioavailability Studies Submitted in NDAs and INDs – General Considerations
Dakshina Chilukuri, PhD.
Team Leader
Division of Infectious Disease Pharmacology (DIDP) | OCP| CDER

1:50 - 2:20: Bioavailability Determination: Special Topics
Jayabharathi Vaidyanathan, PhD.
Associate Director for Therapeutic Review
Division of Cardiometabolic and Endocrine Pharmacology (DCEP) | OCP| CDER

2:20 - 2:40: Break

2:40 - 3:10: Relative Bioavailability Evaluation: Potential for Using Pharmacodynamic and Non-Traditional Pharmacokinetic Endpoints
Kofi A. Kumi, Ph.D., R. Ph.
Senior Reviewer, Clinical Pharmacology
Division of Neuropsychiatric Pharmacology (DNP) | OCP | OTS | CDER

3:10 - 3:40: Recommended In Vitro Studies
Okponanabofa Eradiri, PhD
Branch Chief
Division of Biopharmaceutics (DP) | Office of New Drug Products (ONDP)
Office of Pharmaceutical Quality (OPQ) | CDER | FDA

3:40 - 4:00: Q&A Discussion with All Presenters

FDA RESOURCES

Back to Top